Showing results (71-80 of 96) with videos related to
Sort By:
Pageof 10
European Urology Oncology|March 7, 2022
Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic ChemotherapyBenjamin W Fischer-Valuck, Sagar A Patel, Randall J Brenneman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA Targeted Tubulysin Conjugate EC1169Samir Zaidi, Phillip H Kuo, Tiago Paiva Prudente, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.European Urology|February 25, 2018
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 StudiesGwenaelle Gravis, Jean-Marie Boher, Yu-Hui Chen, et al.International Journal of Radiation Oncology, Biology, Physics|August 12, 2003
The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancerChristopher H Crane, John M Skibber, Elisa H Birnbaum, et al.Cancer|December 21, 2018
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genesPetros Grivas, Amir Mortazavi, Joel Picus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJulie R Brahmer, Charles G Drake, Ira Wollner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2023
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJulie R Brahmer, Charles G Drake, Ira Wollner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)Rahul Aggarwal, Glenn Heller, David W Hillman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2021
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)Jonathan E Rosenberg, Karla A Ballman, Susan Halabi, et al.Pageof 10